Who are Epoetin Alfa-BioManguinhos's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epogen, Erythropoietins (EPO), rHuEPO, epoetin beta [NeoRecormon], epoetin, ARM A : IV iron + epoietin zeta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epoetin-alfa-biomanguinhos.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epoetin Alfa-BioManguinhos — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epoetin Alfa-BioManguinhos (Epoetin Alfa-BioManguinhos) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology.

phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Epoetin Alfa-BioManguinhos (Epoetin Alfa-BioManguinhos) — Hospital de Clinicas de Porto Alegre. Epoetin alfa stimulates erythropoiesis by binding to erythropoietin receptors on bone marrow progenitor cells, promoting red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epoetin Alfa-BioManguinhos TARGET	Epoetin Alfa-BioManguinhos	Hospital de Clinicas de Porto Alegre	phase 3	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
Erythropoietins (EPO)	Erythropoietins (EPO)	Shanghai East Hospital	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
rHuEPO	rHuEPO	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
epoetin beta [NeoRecormon]	epoetin beta [NeoRecormon]	Hoffmann-La Roche	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
epoetin	epoetin	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

Amgen · 4 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
Hospital de Clinicas de Porto Alegre · 2 drugs in this class
Pfizer · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 2 drugs in this class
Barts & The London NHS Trust · 1 drug in this class
Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epoetin Alfa-BioManguinhos — Competitive Intelligence Brief. https://druglandscape.com/ci/epoetin-alfa-biomanguinhos. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab